Introduction
============

Infectious spondylitis, also known as vertebral osteomyelitis, is classified as pyogenic, granulomatous (tuberculous, brucellar, or fungal), or parasitic according to its etiology \[[@B1]\]. Pyogenic spondylitis (PS) refers to a bacterial infection of vertebral bodies and their adjacent intervertebral disc spaces \[[@B2]\].

Microbiologic confirmation is key to the treatment of PS. Staphylococci are the most common bacteria that cause PS \[[@B3][@B4]\]. The prevalence of methicillin-resistant *Staphylococcus aureus* infection has increased in recent decades \[[@B5][@B6]\]; hence, glycopeptide (GP) antibiotics are more frequently considered in clinical practice.

Some studies have described the clinical features and outcomes of culture-negative PS \[[@B7][@B8][@B9]\]. However, the guidelines for proper antibiotic therapy in patients with culture-negative PS have not been well established. A few recent studies noted an increasing incidence of PS with no identified pathogen \[[@B8][@B9][@B10]\].

In the present study, we analyzed the clinical characteristics and treatment regimens of patients with culture-negative PS and determined whether empiric GP antibiotic use could influence clinical outcomes in these patients.

Materials and Methods
=====================

1. Study setting and subjects {#sec1}
-----------------------------

We retrospectively reviewed the medical records of patients diagnosed with infectious spondylitis who visited Seoul St. Mary\'s Hospital (a tertiary referral teaching hospital in Seoul, Korea) between January 2009 and December 2016.

The diagnosis of PS was based on clinical features, laboratory and imaging findings, tissue pathological findings, and culture results, which led to the medical decision on antibiotic therapy and the compatible response. Cases in which specimen culture results and/or histological findings were consistent with those of granulomatous inflammation or fungal infection were excluded. PS was classified as culture-positive or culture-negative according to the results of bacterial cultures obtained using blood and/or tissue specimens. Some patients presumed to have PS were excluded from our analyses if they refused treatment, were noncompliant with medical decisions, had incomplete information regarding antibiotic treatment, or did not undergo both blood and tissue cultures.

Patients with negative culture results were grouped according to the duration of GP antibiotic (vancomycin \[VAN\] or teicoplanin) treatment: GP therapy \<28 days (Group A) and GP therapy ≥28 days (Group B). GP antibiotic treatment included both first-line (initial empiric) and second-line therapy containing GP antibiotics.

Empiric antibiotics were selected based on the physician\'s preference or consultation with infectious disease specialists, which was probably influenced by clinical risk factors such as recent hospitalization, invasive device use, hemodialysis, and surgery. The reasons for changing antibiotics, including GP antibiotics during the treatment period, were largely due to suspected treatment failure; the microorganisms cultured, including colonizers from other sites; and adverse drug effects. The doses of GP antibiotics were adjusted according to estimated glomerular filtration rates and serum GP levels were monitored. Decisions regarding surgical treatment options were based on the surgeon\'s discretion according to the characteristics of individual patients.

The protocol of the present study was reviewed and approved by the Institutional Review Board of Seoul St. Mary\'s Hospital, The Catholic University of Korea (approval no. KC19RESI0232). The requirements for informed consent were waived by the board.

2. Data collection {#sec2}
------------------

During the study period, we extracted data from the electronic hospital database. We reviewed patient-related data regarding demographics, underlying diseases, admission, presenting symptoms (fever, back pain, and neurologic deficit), radiologic findings (involved vertebras and presence of abscesses), laboratory data (white blood cell count, C-reactive protein \[CRP\] level, and erythrocyte sedimentation rate \[ESR\]), blood and tissue culture results, spinal tissue histopathologic findings, medical treatment including GP antibiotic infusion and percutaneous drainage, surgery, recurrence, and death during follow-up.

Previous spinal procedures included acupuncture, spinal injections, nerve block, neuroplasty, vertebroplasty, and surgery. Symptom duration was defined as the time from the onset of symptoms to the day of admission or first outpatient visit. Laboratory data were obtained at the time of admission (or first outpatient visit) or radiologic imaging if patients were already hospitalized due to another disease.

Recurrent infection was defined as one that recurred with clinical features, laboratory values, and/or imaging findings consistent with those of PS after completion of treatment and in which a second course of antibiotics was administered. Time to recurrence denoted the time between the last day of antibiotic administration and the next hospital visit with the same illness or the first day of administration of a second course of antibiotics.

3. Statistical analysis {#sec3}
-----------------------

Variables are expressed as the frequency (%), mean ± standard deviation, or median (interquartile range \[IQR\]). The Mann-Whitney test was used to compare continuous variables between the 2 groups and Pearson\'s chi-squared test or Fisher\'s exact test for categorical variables, as appropriate. All statistical analyses were performed using SPSS version 21.0 (SPSS Korea, Seoul, Korea). A two-tailed *P*-value \<0.05 was considered statistically significant.

Results
=======

During the study period, a total of 175 patients with PS were screened ([Fig. 1](#F1){ref-type="fig"}). Of 78 eligible patients with negative culture results, 66 patients received GP antibiotic treatment for \<28 days (Group A) and 12 patients for ≥28 days (Group B). Fifty-three of the patients in Group A received no GP antibiotics.

![Study flow chart.](ic-51-274-g001){#F1}

1. Clinical characteristics {#sec1___1}
---------------------------

[Table 1](#T1){ref-type="table"} shows the demographics and clinical characteristics of patients with culture-negative PS. The mean age of these patients was 65.5 years, and 52.6% were male. Five of 66 patients (7.5%) in Group A were treated with oral antibiotics alone without admission. The length of hospitalization was significantly longer in Group B compared with that in Group A (Group A, 21.5 \[IQR, 11.2 -- 34.0\] days; Group B, 57.0 \[IQR, 28.7 -- 78.5\] days; *P* \<0.001). Based on the underlying diseases, the rates of previous spinal procedures were significantly different between Groups A and B (Group A, 37/66 \[56.1%\]; Group B, 11/12 \[91.7%\]; *P* = 0.024). Back pain was noted in 75/78 (96.2%) patients and fever in only 7/77 (9.1%). There were no differences in the incidences of associated symptoms of fever, back pain, and neurologic deficit between the 2 groups. Regarding laboratory data, ESRs were significantly higher in Group B than in Group A (Group A, 61.1 ± 26.3 mm/h; Group B, 93.8 ± 24.4 mm/h; *P* \<0.001). CRP levels were also significantly higher in Group B (Group A, 3.4 \[IQR, 1.2 -- 7.5\] mg/dL; Group B, 8.8 \[IQR, 3.7 -- 18.8\] mg/dL; *P* = 0.006).

###### Demographic and clinical characteristics of patients with culture-negative pyogenic spondylitis
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  Characteristics                                   Total (n = 78)                                    Group A (n = 66)       Group B (n = 12)       *P*-value               
  ------------------------------------------------- ------------------------------------------------- ---------------------- ---------------------- ----------------------- ---------
  Male                                              41 (52.6)                                         35 (53.0)              6 (50)                 0.847                   
  Age, mean ± SD, years                             65.5 ± 13.3                                       64.5 ± 14.1            71.3 ± 5.7             0.108                   
  Duration of admission, median (IQR), days         23.0 (14.5--36.0)                                 21.5 (11.2--34.0)      57.0 (28.7--78.5)      \<0.001                 
  Transfer from other hospitals                     21 (26.9)                                         15 (22.7)              6 (50)                 0.075                   
  Underlying disease                                                                                                                                                        
                                                    Diabetes mellitus                                 15 (19.2)              12 (18.2)              3 (25)                  0.691
                                                    Cardiovascular disease/Congestive heart failure   9 (11.5)               7 (10.6)               2 (16.7)                0.622
                                                    Malignancy                                        7 (9.0)                4 (6.1)                3 (25)                  0.069
                                                    Liver cirrhosis                                   3 (3.8)                2 (3.0)                1 (8.3)                 0.398
                                                    End-stage renal disease                           2 (2.6)                2 (3.0)                0 (0)                   \>0.999
  Symptoms at diagnosis                                                                                                                                                     
                                                    Fever, ≥38°C                                      7/77^a^ (9.1)          5/65^a^ (7.7)          2 (16.7)                0.298
                                                    Back pain                                         75 (96.2)              65 (98.5)              10 (83.3)               0.060
                                                    Neurologic deficit                                30 (38.5)              23 (34.8)              7 (58.3)                0.196
  Symptom duration^b^, median (IQR), days           14.0 (5.0--39.0)                                  22.0 (5.0--43.0)       12.5 (5.0--19.2)       0.403                   
  Antibiotic initiation before obtaining cultures   42/75^a^ (56.0)                                   34/64^a^ (53.1)        8/11^a^ (72.7)         0.328                   
  Laboratory data                                                                                                                                                           
                                                    WBC, median (IQR), /mm^3^                         8,030 (6,527--9,575)   8,030 (6,570--9,492)   8,315 (5,942--10,177)   0.967
                                                    CRP^c^, median (IQR), mg/dL                       4.1 (1.3--8.1)         3.4 (1.2--7.5)         8.8 (3.7--18.8)         0.006
                                                    ESR^d^, mean ± SD, mm/h                           66.3 ± 28.5            61.1 ± 26.3            93.8 ± 24.4             \<0.001
  Location                                                                                                                                          \>0.999                 
                                                    Cervical                                          1 (1.3)                1 (1.5)                0 (0)                   
                                                    Thoracic                                          8 (10.3)               7 (10.6)               1 (8.3)                 
                                                    Lumbar                                            50 (64.1)              41 (62.1)              9 (75)                  
                                                    Sacral                                            1 (1.3)                1 (1.5)                0 (0)                   
                                                    Cervicothoracic                                   0 (0)                  0 (0)                  0 (0)                   
                                                    Thoracolumbar                                     4 (5.1)                4 (6.1)                0 (0)                   
                                                    Lumbosacral                                       14 (17.9)              12 (18.2)              2 (16.7)                
  No. of involved vertebrae, mean ± SD              2.3 ± 0.9                                         2.3 ± 0.9              2.3 ± 0.7              0.633                   
  Associated abscess                                23 (29.5)                                         18 (27.3)              5 (41.7)               0.322                   
                                                    Paraspinal abscess                                18 (23.1)              14 (21.2)              4 (33.3)                0.457
                                                    Epidural abscess                                  2 (2.6)                2 (3.0)                0 (0)                   \>0.999
                                                    Psoas abscess                                     6 (7.7)                5 (7.6)                1 (8.3)                 \>0.999
  Previous spinal procedure                         48 (61.5)                                         37 (56.1)              11 (91.7)              0.024                   
  Previous spinal surgery                           38 (48.7)                                         28 (42.4)              10 (83.3)              0.009                   
  Presence of spinal implant                        22 (28.2)                                         16 (24.2)              6 (50)                 0.087                   

Data are presented as n (%) unless otherwise specified.

^a^n/total with available information (%).

^b^Missing data in 31/78 (39.7%) patients: 27/66 (40.9%) in Group A, and 4/12 (33.3%) in Group B.

^c^Missing data in 1/78 (1.3%) patients: 1/66 (1.5%) in Group A, and 0/12 (0%) in Group B.

^d^Missing data in 3/78 (3.8%) patients: 3/66 (4.5%) in Group A, and 0/12 (0%) in Group B.

SD, standard deviation; IQR, interquartile range; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.

Regarding imaging modalities for the diagnosis of PS, magnetic resonance imaging was performed in 74/78 (94.9%) patients, and computed tomography alone without magnetic resonance imaging was used to localize the spinal lesions in 4/78 (5.1%) patients. The mean number of involved vertebrae was 2.3 ± 0.9, and the lumbar vertebra was the most frequently affected region (64.1%), followed by the lumbosacral and thoracic vertebrae (17.9% and 10.3%, respectively). Accompanying abscesses were found in 29.5% (23/78) of patients. At the time of diagnosis, 22/78 (28.2%) patients had spinal implants.

2. Microbiologic tests {#sec2___1}
----------------------

Blood cultures were performed in 82.1% (64/78) of patients with negative culture results, tissue cultures in 61.5% (48/78), and both blood and tissue cultures in only 43.6% (34/78). Tissue samples were obtained via percutaneous (18/48, 37.5%) or surgical (30/48, 62.5%) biopsy. No second biopsies were obtained for patients with negative culture results. Prior to culture sampling, 42/75 (56.0%) patients had been exposed to antibiotics.

The pathogens identified in patients with culture-positive PS are shown in [Supplementary Table 1](#S1){ref-type="supplementary-material"}. Staphylococci were the most commonly isolated pathogens (50.6%, 42 of 83 culture-positive cases), and 54.7% of these cases were methicillin-resistant. The next most common pathogens were *Streptococcus* species (14.5%, 12/83) and Enterobacteriaceae (10.8%, 9/83).

3. Treatment and outcomes {#sec3___1}
-------------------------

[Table 2](#T2){ref-type="table"} shows the treatment and clinical outcomes among patients with culture-negative PS. The median follow-up duration was 573 (IQR, 83 -- 1,037) days. Of 78 patients with negative culture results, 44 (56.4%) received only medical therapy, and the rest (43.6%) underwent both medical and surgical treatment. Percutaneous abscess drainage was performed in only 1 of 41 medically treated patients in Group A. Surgical treatment included debridement, discectomy, laminectomy, spinal instrumentation, bone graft, and implant replacement. The treatment modalities were significantly different between the groups (*P* = 0.017); Group B (75%) had a higher proportion of patients with combined treatment of medical therapy and surgery than Group A (37.9%).

###### Treatment and outcomes of culture-negative pyogenic spondylitis
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  Treatment/Outcomes                       Total (n = 78)       Group A (n = 66)   Group B (n = 12)   *P*-value
  ---------------------------------------- -------------------- ------------------ ------------------ -----------
  Treatment                                                                                           0.017
                                           Medical              44 (56.4)          41 (62.1)          3 (25)
                                           Medical + Surgical   34 (43.6)          25 (37.9)          9 (75)
  Follow-up duration, median (IQR), days   573 (83--1,037)      621 (77--1,083)    302 (127--872)     0.879
  Recurrence                               7 (9.0)              5 (7.6)            2 (16.7)           0.293
  In-hospital mortality                    0 (0)                0 (0)              0 (0)              

Data are presented as n (%) unless otherwise specified.

IQR, interquartile range.

The types of antibiotics used and the duration of antibiotic treatment are shown in [Table 3](#T3){ref-type="table"}, which includes those from referring hospitals. Antibiotic therapies administered before sampling included GP-containing regimens (47.6%), third-generation cephalosporins (30.9%), first-generation cephalosporins (21.4%), second-generation cephalosporins (14.2%), beta-lactam/beta-lactamase inhibitor (11.9%), quinolone ± beta-lactam (9.5%), and others (21.4%). During the entire treatment period, 8 of 77 (10.4%) patients received only parenteral antibiotics, and 6 of 78 (7.7%) patients received only oral antibiotics. Apart from GP-containing regimens, the intravenous antibiotics administered were cefazolin (42.3%), ampicillin/sulbactam (32.1%), third-generation cephalosporin (19.2%), piperacillin/tazobactam (12.8%), *etc*., in descending order of frequency. Carbapenem was more commonly used in Group B (*P* = 0.011). Therapeutic regimens containing GP included combinations of GP antibiotics, broad-spectrum cephalosporin, and others (20.5%); GP antibiotics alone (12.8%); combinations of GP antibiotics and quinolone (7.7%); combinations of GP antibiotics and beta-lactam/beta-lactamase inhibitor (7.7%); and combinations of GP antibiotics and a carbapenem (6.4%). Infused GP antibiotics comprised VAN (63.6%) and teicoplanin (36.4%). Among 12 patients in Group B, 7 patients (58.3%) received GP antibiotics as initial empiric therapy, while 5 patients (41.7%) received them as second-line therapy. Except for oral treatment alone, almost all oral antibiotics were administered as a switch therapy from intravenous antibiotics. The most commonly used oral antibiotic was amoxicillin/clavulanate (23.4%) followed by quinolone (22.1%), second-generation cephalosporin (22.1%), third-generation cephalosporin (20.8%), and first-generation cephalosporin (11.7%).

###### Therapeutic antibiotics in patients with culture-negative pyogenic spondylitis
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  Antibiotic regimens                                 Total (n = 78)                        Group A (n = 66)                                       Group B (n = 12)      *P*-value                      
  --------------------------------------------------- ------------------------------------- ------------------------------------------------------ --------------------- ------------------- ---------- ---------
  Intravenous antibiotics                                                                                                                                                                               
                                                      Monotherapy                                                                                                                                       
                                                                                            Cefazolin                                              33 (42.3)             29 (43.9)           4 (33.3)   0.494
                                                                                            Ampicillin/sulbactam                                   25 (32.1)             24 (36.4)           1 (8.3)    0.090
                                                                                            3rd-generation cephalosporin                           15 (19.2)             14 (21.2)           1 (8.3)    0.443
                                                                                            Piperacillin/tazobactam                                10 (12.8)             8 (12.1)            2 (16.7)   0.647
                                                                                            Quinolone                                              4 (5.1)               3 (4.5)             1 (8.3)    0.495
                                                                                            2nd-generation cephalosporin                           4 (5.1)               4 (6.1)             0 (0)      \>0.999
                                                                                            Carbapenem                                             4 (5.1)               1 (1.5)             3 (25)     0.011
                                                      Combination therapy                                                                                                                               
                                                                                            Beta-lactam + quinolone                                5 (6.4)               4 (6.1)             1 (8.3)    0.577
                                                                                            Beta-lactam + aminoglycoside                           4 (5.1)               3 (4.5)             1 (8.3)    0.495
                                                                                            3rd-generation cephalosporin + metronidazole           3 (3.8)               3 (4.5)             0 (0)      \>0.999
                                                      Glycopeptide-containing regimens                                                                                                                  
                                                                                            Glycopeptide + broad-spectrum cephalosporin ± others   16 (20.5)             7 (10.6)            9 (75)     \<0.001
                                                                                            Glycopeptide alone                                     10 (12.8)             5 (7.6)             5 (41.7)   0.006
                                                                                            Glycopeptide + quinolone                               6 (7.7)               2 (3.0)             4 (33.3)   0.004
                                                                                            Glycopeptide + beta-lactam/beta-lactamase inhibitor    6 (7.7)               2 (3.0)             4 (33.3)   0.004
                                                                                            Glycopeptide + carbapenem                              5 (6.4)               1 (1.5)             4 (33.3)   0.002
                                                                                            Glycopeptide + others                                  3 (3.8)               1 (1.5)             2 (16.7)   0.060
                                                      Others                                7 (9.0)                                                7 (10.6)              0 (0)               0.587      
                                                      No intravenous antibiotic use         6 (7.7)                                                6 (9.1)               0 (0)               0.582      
  Oral antibiotics                                                                                                                                                                                      
                                                      Amoxicillin/clavulanate               18/77^a^ (23.4)                                        15/65^a^ (23.1)       3 (25)              \>0.999    
                                                      Quinolone                             17/77^a^ (22.1)                                        14/65^a^ (21.5)       3 (25)              0.721      
                                                      2nd-generation cephalosporin          17/77^a^ (22.1)                                        16/65^a^ (24.6)       1 (8.3)             0.282      
                                                      3rd-generation cephalosporin          16/77^a^ (20.8)                                        14/65^a^ (21.5)       2 (16.7)            \>0.999    
                                                      1st-generation cephalosporin          9/77^a^ (11.7)                                         9/65^a^ (13.8)        0 (0)               0.340      
                                                      Amoxicillin                           2/77^a^ (2.6)                                          2/65^a^ (3.1)         0 (0)               \>0.999    
                                                      Amoxicillin/clavulanate + quinolone   2/77^a^ (2.6)                                          2/65^a^ (3.1)         0 (0)               \>0.999    
                                                      Others                                5/77^a^ (6.5)                                          2/65^a^ (3.1)         3 (25)              0.025      
                                                      No oral antibiotic use                8/77^a^ (10.4)                                         5/65^a^ (7.7)         3 (25)              0.104      
  Antibiotic duration, total^b^, median (IQR), days   73.0 (47.0--104.0)                    67.0 (44.0--94.5)                                      113.0 (67.0--172.2)   0.005                          
                                                      Intravenous^c^                        32.0 (20.0--56.0)                                      28.0 (16.5--40.0)     75.5 (56.0--95.5)   \<0.001    
                                                      Oral^d^                               41.0 (19.0--63.5)                                      41.0 (19.5--63.5)     32.5 (0.0--81.2)    0.757      

Data are presented as n (%) unless otherwise specified.

^a^n/total with available information (%).

^b,\ c,\ d^Missing data in 1/78 (1.2%) patients: 1/66 (1.5%) in Group A, and 0/12 (0%) in Group B.

IQR, interquartile range.

The duration of pre-sampling antibiotic use was 11.0 (IQR, 2.0 -- 22.0) days. The total antibiotic treatment duration, including periods of both parenteral and oral administration, was significantly different between the 2 groups (Group A, 67.0 \[IQR, 44.0 -- 94.5\] days; Group B, 113.0 \[IQR, 67.0 -- 172.2\] days; *P* = 0.005). The duration of intravenous antibiotic therapy was significantly longer in Group B than in Group A (Group A, 28.0 \[IQR, 16.5 -- 40.0\] days; Group B, 75.5 \[IQR, 56.0 -- 95.5\] days; *P* \<0.001), but there was no difference in the duration of oral antibiotic treatment (*P* = 0.757). The median duration of intravenous GP antibiotic therapy was 0.0 (IQR, 0.0 -- 0.0) days and 55.5 (IQR, 37.0 -- 75.7) days for Groups A and B, respectively (*P* \<0.001).

Recurrence was noted in 7 (9.0%) of 78 patients with culture-negative PS. The recurrence rate was not significantly different between the 2 groups, but was higher in Group B than in Group A (Group A, 5/66 \[7.6%\]; Group B, 2/12 \[16.7%\]; *P* = 0.293). The median time to recurrence was 68 (range, 9 -- 193) days. Spondylitis-related deaths did not occur during hospitalization, but 2 patients with malignancy and 1 with end-stage renal disease died during the follow-up period.

Discussion
==========

This single-center retrospective study described the clinical characteristics and outcomes in patients with culture-negative PS who were divided into 2 groups according to the GP treatment duration: GP antibiotic treatment for \<28 days, and GP antibiotic treatment for ≥28 days.

In our study, pathogens were not identified in 51.7% of patients with PS. As many as 56% of patients with culture-negative PS received antibiotics before specimen collection. Although GP antibiotic monotherapy was used in some cases, most of our empiric GP-containing regimens comprised combinations covering Gram-positive organisms including staphylococci and streptococci and Gram-negative bacilli.

The recurrence rate of PS was reported to be 0 -- 15% in previous studies \[[@B11]\]. In our study, the recurrence rate of culture-negative PS was 9.0% (7/78), which was not different from that of culture-positive PS (11.0% \[8/73\], *P* = 0.684). The mortality rate of vertebral osteomyelitis has been reported to be 0 -- 30% with a recent decline \[[@B12][@B13]\]. In a study comparing culture-negative PS with culture-positive PS, when spinal surgery cases were excluded, a higher CRP level was found to be a risk factor for treatment failure in culture-negative PS \[[@B9]\]. Some authors have reported that culture-negative PS is related to lower inflammation levels compared with culture-positive PS, possibly due to small inocula of pathogens \[[@B8][@B9]\]. However, studies comparing culture-negative and culture-positive groups showed mixed outcomes \[[@B8][@B9][@B14][@B15]\].

There has been insufficient research about the optimal selection of empirical antibiotics in patients with culture-negative PS. There was a report of a favorable outcome when cefazolin was used in hematogenous PS and when VAN was used in post-procedural PS \[[@B15]\]. Some studies revealed that empiric antibiotic regimens comprising levofloxacin and rifampicin in culture-negative PS were as effective as treatments tailored according to culture results in microbiologically confirmed PS \[[@B16]\]. Moreover, patients with spontaneous PS without microbiological diagnoses who were treated with amoxicillin/clavulanate and ciprofloxacin showed results similar to those of patients who received targeted antimicrobial therapy in a retrospective study \[[@B17]\]. Although the data were not presented, antibiotic regimens containing rifampicin were infrequently used in our study.

A high percentage of patients in the present study previously underwent spinal procedures including surgery, especially in the group with longer GP antibiotic treatment (spinal procedure, 11/12 \[91.7%\]; spinal surgery, 10/12 \[83.3%\]). PS that occurs after spinal surgery or procedure is usually associated with more resistant microorganisms and removal of implants may be unavoidable \[[@B9]\]. Coagulase-negative staphylococci and *Propionibacterium acnes* are found mostly in PS after spinal surgery or instrumentation \[[@B18]\]. In prosthetic device infection, biofilm formation is frequently associated with treatment failure \[[@B19]\]. Treating physicians tend to choose GP antibiotics in patients with prior spinal surgery.

Our study showed that in the group with longer GP antibiotic treatment, the length of hospital stay and the duration of antibiotic treatment were longer; the levels of inflammatory markers such as CRP or ESR were higher; and more surgical procedures were performed. Moreover, this group showed more frequent recurrence, although this trend was not statistically significant. This may be due to the severity of spondylitis and the risk factors of patients. This result implies that the main determinants of clinical outcomes are not only GP antibiotic use and the duration of GP antibiotic treatment, but also the severity and associated risk factors. In addition, the shorter follow-up duration in the group that received GP antibiotics for a longer period, although not significant, may have led to this non-significant difference in recurrence rates.

The present study had several limitations. The relatively small sample size reduced the power of the evidence, and the retrospective nature conferred some inherent selection and misclassification biases. There were no standardized criteria among physicians, surgeons, treating departments, and referring clinics as regards the selection of medical or surgical treatment options in our study population. Antimicrobial regimens were too diverse in antibiotic type and treatment length between groups to compare the exact effects of specific antibiotics among patients with PS. Furthermore, the comparison of outcomes such as recurrence via multivariate analyses was not performed due to low event rates. The enrolled cases covered healthcare associated PS, including post-surgical infection. Thus, our results do not purely and simply reflect the characteristics of community-acquired PS. Due to the heterogeneity in the groups, our results should be interpreted with caution. In addition, data regarding therapeutic monitoring of GP antibiotics and adverse drug events were not evaluated.

Therefore, it is not clear from this study whether the use or duration of empiric GP antibiotic treatment can influence clinical outcomes in patients with PS that has not been confirmed via microbiology. However, it is prudent to consider GP antibiotics in patients at high risk for infection with resistant pathogens. Further large-scale prospective studies are needed to obtain more evidence for appropriate antibiotic treatment.
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SUPPLEMENTARY MATERIAL
======================

###### Supplementary Table 1

Microorganisms isolated from the blood and/or tissue of patients with pyogenic spondylitis
